Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATAINASDAQ:CRDLNASDAQ:ORICNASDAQ:URGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATAIAtai Life Sciences$2.06+2.0%$1.47$1.03▼$2.57$412.70M1.221.58 million shs1.71 million shsCRDLCardiol Therapeutics$1.10+2.8%$1.04$0.77▼$3.12$90.87M0.98364,275 shs198,500 shsORICORIC Pharmaceuticals$6.35+6.7%$5.41$3.90▼$14.67$451.41M1.37657,399 shs911,637 shsURGNUroGen Pharma$4.19+2.7%$10.03$3.42▼$20.70$193.19M0.66671,011 shs2.33 million shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATAIAtai Life Sciences+1.98%+24.85%+35.53%+3.52%+23.35%CRDLCardiol Therapeutics+2.80%-0.90%+1.85%-8.33%-49.54%ORICORIC Pharmaceuticals+6.72%+34.25%+22.47%-17.32%-30.75%URGNUroGen Pharma+2.70%-42.68%-58.92%-58.43%-68.52%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATAIAtai Life Sciences2.3065 of 5 stars3.71.00.00.02.52.50.6CRDLCardiol Therapeutics1.5299 of 5 stars3.73.00.00.00.00.00.6ORICORIC Pharmaceuticals4.4792 of 5 stars4.52.00.04.33.31.70.6URGNUroGen Pharma3.9867 of 5 stars4.41.00.04.52.31.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATAIAtai Life Sciences 3.33Buy$8.67320.71% UpsideCRDLCardiol Therapeutics 3.40Buy$8.67687.88% UpsideORICORIC Pharmaceuticals 3.00Buy$19.17201.84% UpsideURGNUroGen Pharma 2.88Moderate Buy$27.43554.62% UpsideCurrent Analyst Ratings BreakdownLatest CRDL, ATAI, URGN, and ORIC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/23/2025URGNUroGen PharmaGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $15.005/22/2025URGNUroGen PharmaThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$16.00 ➝ $3.005/22/2025URGNUroGen PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral5/20/2025ATAIAtai Life SciencesJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$5.005/20/2025ATAIAtai Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.005/13/2025ATAIAtai Life SciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/13/2025URGNUroGen PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$55.00 ➝ $55.005/8/2025URGNUroGen PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.005/6/2025ORICORIC PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$15.00 ➝ $12.005/6/2025ORICORIC PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight5/5/2025ORICORIC PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$21.00 ➝ $21.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATAIAtai Life Sciences$1.86M221.52N/AN/A$1.47 per share1.40CRDLCardiol TherapeuticsN/AN/AN/AN/A$0.32 per shareN/AORICORIC PharmaceuticalsN/AN/AN/AN/A$3.42 per shareN/AURGNUroGen Pharma$91.87M2.10N/AN/A($2.78) per share-1.51Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATAIAtai Life Sciences-$40.22M-$0.91N/AN/AN/AN/A-65.75%-52.71%8/12/2025 (Estimated)CRDLCardiol Therapeutics-$20.84M-$0.34N/AN/AN/AN/A-194.40%-129.07%7/14/2025 (Estimated)ORICORIC Pharmaceuticals-$100.70M-$1.87N/AN/AN/AN/A-44.54%-40.72%8/11/2025 (Estimated)URGNUroGen Pharma-$102.24M-$3.18N/AN/AN/A-129.11%N/A-47.94%8/12/2025 (Estimated)Latest CRDL, ATAI, URGN, and ORIC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025ATAIAtai Life Sciences-$0.19-$0.15+$0.04-$0.15N/A$1.56 million5/12/2025Q1 2025URGNUroGen Pharma-$0.83-$0.92-$0.09-$0.92$22.71 million$20.25 million5/5/2025Q1 2025ORICORIC Pharmaceuticals-$0.51-$0.42+$0.09-$0.42N/AN/A3/31/2025Q4 2024CRDLCardiol Therapeutics-$0.08-$0.07+$0.01-$0.07N/AN/A3/17/2025Q4 2024ATAIAtai Life Sciences-$0.14-$0.24-$0.10-$0.24$0.30 million($0.01) million3/10/2025Q4 2024URGNUroGen Pharma-$0.69-$0.80-$0.11-$0.80$25.25 million$24.57 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATAIAtai Life SciencesN/AN/AN/AN/AN/ACRDLCardiol TherapeuticsN/AN/AN/AN/AN/AORICORIC PharmaceuticalsN/AN/AN/AN/AN/AURGNUroGen PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATAIAtai Life Sciences0.145.815.81CRDLCardiol Therapeutics0.012.492.49ORICORIC PharmaceuticalsN/A10.5613.15URGNUroGen Pharma4.779.008.77Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATAIAtai Life Sciences28.41%CRDLCardiol Therapeutics12.49%ORICORIC Pharmaceuticals95.05%URGNUroGen Pharma91.29%Insider OwnershipCompanyInsider OwnershipATAIAtai Life Sciences31.20%CRDLCardiol Therapeutics5.25%ORICORIC Pharmaceuticals6.82%URGNUroGen Pharma5.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATAIAtai Life Sciences80200.34 million115.45 millionOptionableCRDLCardiol Therapeutics2082.61 million78.27 millionNot OptionableORICORIC Pharmaceuticals8071.09 million67.09 millionOptionableURGNUroGen Pharma20046.11 million22.26 millionOptionableCRDL, ATAI, URGN, and ORIC HeadlinesRecent News About These CompaniesUroGen Pharma (NASDAQ:URGN) Price Target Cut to $3.00 by Analysts at The Goldman Sachs GroupMay 24 at 10:49 AM | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGNMay 24 at 9:00 AM | accessnewswire.comHC Wainwright Reiterates "Neutral" Rating for UroGen Pharma (NASDAQ:URGN)May 24 at 8:10 AM | marketbeat.comKaplan Fox is Investigating Potential Securities Law Violations against UroGen Pharma Ltd. (URGN)May 23 at 3:41 PM | theglobeandmail.comOngoing Securities Investigation into UroGen Pharma Ltd. (URGN) - Contact Levi & KorsinskyMay 23 at 1:00 PM | accessnewswire.comUroGen Pharma Ltd. (URGN) Shares Crash Again Amid FDA's ODAC Vote Against UGN-102, Company Facing Investor Scrutiny - Hagens BermanMay 23 at 12:30 PM | accessnewswire.comHC Wainwright & Co. Downgrades UroGen Pharma (URGN)May 23 at 10:40 AM | msn.comPotential Securities Fraud: Levi & Korsinsky Investigates UroGen Pharma Ltd. (URGN)May 23 at 10:15 AM | accessnewswire.comUroGen Pharma Ltd. (URGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the InvestigationMay 23 at 10:00 AM | accessnewswire.comPoint72 Asset Management L.P. Sells 1,189,532 Shares of UroGen Pharma Ltd. (NASDAQ:URGN)May 23 at 4:36 AM | marketbeat.comURGN ACTIVE INVESTIGATION: Lost Money on UroGen Pharma Ltd.? Contact Levi & Korsinsky NowMay 22 at 5:15 PM | accessnewswire.comUroGen Pharma Ltd. (URGN) Shares Crash Again Amid FDA's ODAC Vote Against UGN-102, Company Facing Investor Scrutiny – Hagens BermanMay 22 at 5:04 PM | globenewswire.comUroGen tanks as FDA panel vote goes against UGN-102May 22 at 2:03 PM | thepharmaletter.comLost Money on UroGen Pharma Ltd. (URGN)? Contact Levi & Korsinsky About InvestigationMay 22 at 10:30 AM | accessnewswire.comBronstein, Gewirtz & Grossman, LLC Announces an Investigation Against UroGen Pharma Ltd. (URGN) and Encourages Stockholders to Learn More About the InvestigationMay 22 at 10:00 AM | accessnewswire.com1,749,142 Shares in UroGen Pharma Ltd. (NASDAQ:URGN) Bought by Toronto Dominion BankMay 22 at 5:05 AM | marketbeat.comUroGen Stock Slumps After FDA Advisory Committee Flag Concerns On Its Investigational Drug: But Retail’s UnruffledMay 21 at 10:58 PM | msn.comWhat's Going On With UroGen Pharma Stock Wednesday?May 21 at 5:57 PM | benzinga.comUroGen crashes as FDA AdCom rebukes bladder cancer drugMay 21 at 5:57 PM | msn.comUroGen Pharma: ODAC Decision Puts Drug Approval In Limbo, But It's Not Over, EitherMay 21 at 5:57 PM | seekingalpha.comLost Money on UroGen Pharma Ltd. (URGN)? Contact Levi & Korsinsky About Fraud InvestigationMay 21 at 5:15 PM | accessnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCRDL, ATAI, URGN, and ORIC Company DescriptionsAtai Life Sciences NASDAQ:ATAI$2.06 +0.04 (+1.98%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$2.09 +0.03 (+1.46%) As of 05/23/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.Cardiol Therapeutics NASDAQ:CRDL$1.10 +0.03 (+2.80%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.12 +0.02 (+1.82%) As of 05/23/2025 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.ORIC Pharmaceuticals NASDAQ:ORIC$6.35 +0.40 (+6.72%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$6.60 +0.25 (+3.94%) As of 05/23/2025 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.UroGen Pharma NASDAQ:URGN$4.19 +0.11 (+2.70%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$4.16 -0.04 (-0.84%) As of 05/23/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Trade Desk Silences Critics; Recovery Looks Poised to Continue Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH Stock Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain These ETFs Provide Easy Exposure to Growing International Markets Advance Auto Parts Jumps on Surprise Earnings Beat Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
